International Journal of Emerging Research in Applied Medical Sciences (IJERAMS)

Artificial Intelligence–Driven Digital Twins in Precision Oncology: Transforming Personalized Cancer Diagnosis, Treatment, and Survivorship

Mr. Rohan Deshmukh[1], Dr. Nisha Verma[2], Dr. Aarav Sharma[3], Dr. Meera Kulkarni[4]

[1]Assistant ProfessorDepartment of Pharmacology, Sunrise College of Pharmacy, Jaipur, India. rohan.deshmukh@gmail.com
[2]Professor Department of Pharmacy Practice, Sunrise College of Pharmacy, Jaipur, India. nisha.verma54@gmail.com
[3]Associate Professor Department of Pharmaceutics, Sunrise College of Pharmacy, Jaipur, India. Aarav.sharma@gmail.com
[4] Professor, Department of Pharmaceutical Chemistry Sunrise College of Pharmacy, Jaipur, India. Meera.kulkarni@gmail.com

ABSTRACT

Cancer remains one of the leading causes of morbidity and mortality worldwide despite remarkable advances in molecular biology, precision medicine, and targeted therapeutics. The extraordinary biological heterogeneity observed among tumors, coupled with dynamic interactions between malignant cells, the immune system, and the tumor microenvironment, continues to challenge conventional treatment strategies. Recent developments in artificial intelligence (AI), computational modeling, and multimodal biomedical data integration have introduced the concept of digital twins as a promising framework for personalized oncology. A digital twin is a continuously updated virtual representation of an individual patient that integrates clinical, radiological, pathological, genomic, molecular, physiological, and longitudinal health data to simulate disease progression and therapeutic response. Unlike traditional predictive models that focus on isolated datasets, digital twins enable dynamic patient-specific modeling capable of supporting diagnosis, prognostic prediction, treatment optimization, toxicity assessment, and survivorship management. Advances in machine learning, deep learning, foundation models, graph neural networks, reinforcement learning, and generative AI have significantly enhanced the development of oncology digital twins by enabling real-time integration of heterogeneous biomedical information. These computational systems have demonstrated growing potential across tumor detection, radiogenomics, immunotherapy prediction, adaptive radiation therapy, surgical planning, clinical trial optimization, and precision drug development. Nevertheless, several challenges remain regarding data standardization, interoperability, computational complexity, ethical governance, model transparency, regulatory validation, and large-scale clinical implementation. This review provides a comprehensive overview of digital twin technologies in oncology, highlighting their computational foundations, current clinical applications, emerging innovations, and future role in advancing personalized cancer care.[1]

Keywords: *Digital twins, Precision oncology, Artificial intelligence, Computational oncology, Multimodal learning, Radiogenomics, Personalized medicine, Clinical decision support, Machine learning, Cancer informatics.*

Article History
Received: 10 June 2026; **Accepted:** 15 June 2026; **Published:** 25 June 2026

Citation
Deshmukh. R., (2026). Artificial Intelligence–Driven Digital Twins in Precision Oncology: Transforming Personalized Cancer Diagnosis, Treatment, and Survivorship. *International Journal of Emerging Research in Applied Medical Sciences (IJERAMS), 2(6), 69-77*
DOI: https://doi.org/10.65477/2026.v.2i.6.07

1. Introduction

Cancer remains one of the most biologically Cancer is an extraordinarily complex disease driven by genetic mutations, epigenetic alterations, immune dysregulation, metabolic reprogramming, and continuous interactions between malignant cells and their surrounding microenvironment. Although advances in molecular diagnostics and targeted therapeutics have substantially improved outcomes for many patients, considerable variability in treatment response remains a major obstacle in modern oncology. Patients with apparently similar histopathological diagnoses frequently exhibit remarkably different therapeutic responses, recurrence patterns, and survival outcomes, highlighting the limitations of traditional population-based treatment strategies.[2]

Modern oncology increasingly relies upon large volumes of heterogeneous biomedical information generated from medical imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, laboratory investigations, wearable devices, and electronic health records. While these diverse data sources collectively provide a comprehensive picture of disease biology, their sheer complexity exceeds the interpretive capacity of conventional statistical methods and routine clinical workflows. As a result, clinicians often face challenges in synthesizing multimodal information into individualized treatment decisions.[3]

Artificial intelligence has emerged as one of the most transformative technologies in precision oncology by enabling automated analysis of complex biomedical datasets. Deep learning algorithms have demonstrated remarkable success in image recognition, molecular prediction, clinical risk stratification, and therapeutic outcome forecasting. More recently, advances in computational modeling have expanded beyond isolated predictive algorithms toward integrated virtual representations of individual patients, giving rise to the concept of digital twins.[4]

Digital twins were originally developed within engineering and manufacturing industries to create virtual models capable of continuously monitoring, simulating, and optimizing the performance of physical systems. The same concept has now been adapted to healthcare, where patient-specific computational models integrate multidimensional clinical information to simulate disease evolution, evaluate treatment strategies, and predict future health outcomes. In oncology, digital twins represent one of the most promising developments in personalized medicine because they allow clinicians to virtually evaluate multiple therapeutic scenarios before initiating treatment.[5]

Unlike conventional predictive models that rely on static datasets, oncology digital twins are dynamic systems continuously updated with new clinical information. Radiological imaging, histopathological findings, genomic sequencing, laboratory biomarkers, treatment response, and longitudinal follow-up data are continuously incorporated into the computational model, allowing the virtual patient to evolve alongside the biological patient. This adaptive learning framework provides unprecedented opportunities for individualized cancer management throughout the entire continuum of care.[6]

2. Evolution of Digital Twin Technology in Healthcare

The concept of digital twins originated in industrial engineering, where virtual replicas of complex machinery were developed to optimize operational efficiency, detect faults, and predict maintenance requirements. Aerospace organizations were among the first to employ digital twin technology for monitoring aircraft systems under diverse operational conditions. Similar approaches were subsequently adopted in automotive manufacturing, smart infrastructure, robotics, and energy management.[7]

Healthcare researchers recognized that many principles underlying industrial digital twins could be adapted to biological systems. Instead of modeling mechanical components, computational healthcare twins simulate physiological processes, disease progression, therapeutic interventions, and patient outcomes. Early healthcare digital twins primarily focused on cardiovascular disease, diabetes management, orthopedic biomechanics, and intensive care monitoring, where continuous physiological measurements could be incorporated into predictive computational models.[8]

The rapid expansion of biomedical data acquisition technologies significantly accelerated healthcare digital twin development. High-throughput genomic sequencing, advanced imaging platforms, wearable biosensors, molecular diagnostics, and cloud-based electronic health records collectively enabled continuous generation of patient-specific data streams. Artificial intelligence became essential for processing these massive datasets and transforming them into clinically meaningful predictions.[9]

Cancer medicine emerged as one of the most suitable applications for digital twin technology because oncology requires integration of numerous biological, molecular, imaging, and clinical variables that continuously evolve throughout disease progression. Every patient's tumor exhibits unique molecular characteristics, immune interactions, therapeutic responses, and resistance mechanisms. Consequently, digital twins offer an attractive framework for capturing this biological complexity while supporting personalized treatment decisions.[10]

Today, oncology digital twins extend far beyond simple predictive algorithms. They combine mathematical modeling, systems biology, multimodal artificial intelligence, graph-based representations, mechanistic simulations, and probabilistic inference to create dynamic computational ecosystems capable of representing the entire cancer journey from diagnosis through survivorship.[11]

3. Core Architecture of Oncology Digital Twins

An oncology digital twin consists of several interconnected computational layers that continuously exchange information to create an evolving virtual representation of an individual patient. Rather than functioning as a single artificial intelligence model, digital twins integrate multiple computational components operating simultaneously across different biological scales.[12]

The first layer involves comprehensive data acquisition from diverse clinical sources. These include radiological imaging, digital pathology, genomic sequencing, transcriptomic analysis, proteomic profiling, laboratory biomarkers, physiological monitoring, treatment history, medication records, and electronic health documentation. Each data source contributes complementary information regarding tumor biology and patient health status.[13]

The second layer performs multimodal data harmonization. Since biomedical information is generated using different technologies and formats, sophisticated preprocessing pipelines standardize imaging data, normalize molecular profiles, extract quantitative imaging biomarkers, encode clinical narratives using natural language processing, and align heterogeneous datasets into unified computational representations.[14]

The third layer incorporates advanced artificial intelligence algorithms responsible for predictive modeling. Deep neural networks analyze medical images, transformer architectures process clinical language, graph neural networks model molecular interaction networks, and probabilistic learning algorithms estimate disease progression. Together, these computational methods generate integrated patient-specific biological representations capable of supporting downstream clinical decision-making.[15]

Simulation engines constitute another essential component of oncology digital twins. These mathematical frameworks model tumor growth kinetics, metastatic dissemination, immune responses, therapeutic interventions, and treatment resistance. By continuously incorporating newly acquired patient information, simulation models dynamically update disease trajectories, allowing clinicians to evaluate multiple treatment strategies before implementation.[16]

The final layer involves clinical visualization and decision support. Rather than presenting clinicians with isolated predictions, digital twins generate comprehensive patient dashboards illustrating predicted disease progression, therapeutic response probabilities, toxicity risks, survival estimates, and recommended treatment pathways. These interactive interfaces facilitate multidisciplinary decision-making while maintaining physician oversight throughout the clinical workflow.[17]

4. Artificial Intelligence Technologies Powering Digital Twins

The remarkable capabilities of oncology digital twins depend heavily on recent advances in artificial intelligence. Multiple complementary AI techniques work together to transform raw biomedical data into clinically actionable insights.[18]

Machine learning algorithms initially formed the computational foundation of digital twin development by identifying statistical relationships between clinical variables and patient outcomes. Random forests, support vector machines, and gradient boosting algorithms demonstrated considerable success in predicting recurrence risk, treatment response, and survival across several malignancies. Although effective, these models were often limited by their reliance on manually engineered features and structured datasets.[19]

Deep learning significantly expanded predictive capabilities by automatically extracting hierarchical representations from high-dimensional biomedical data. Convolutional neural networks enabled automated interpretation of pathology slides, radiological images, and microscopic tissue architecture, while recurrent neural networks facilitated temporal analysis of longitudinal clinical information.[20]

Transformer architectures have recently become central to digital twin development because they efficiently process large multimodal datasets while preserving long-range contextual relationships. Self-attention mechanisms enable simultaneous analysis of imaging findings, genomic profiles, pathology reports, and clinical documentation, generating integrated patient representations that support highly personalized therapeutic recommendations.[21]

Foundation models further enhance scalability by learning generalized biomedical representations from enormous collections of unlabeled medical data. After pretraining, these models can be adapted to numerous oncology applications through transfer learning, substantially reducing dependence on manually annotated datasets while improving generalizability across different cancer types.[22]

5. Multimodal Data Integration: The Foundation of Oncology Digital Twins

The effectiveness of oncology digital twins depends on their ability to integrate diverse biomedical information into a unified computational framework. Cancer is a multifactorial disease in which tumor behavior is influenced by genetic mutations, epigenetic modifications, cellular metabolism, immune interactions, anatomical characteristics, treatment history, and patient-specific clinical variables. Consequently, relying on a single source of information rarely captures the full biological complexity of an individual malignancy. Digital twins overcome this limitation by continuously combining multimodal data to generate a comprehensive virtual representation of each patient.[23]

Medical imaging contributes anatomical and functional information regarding tumor size, morphology, vascularity, metabolic activity, and disease progression. Histopathological analysis provides microscopic evaluation of tumor architecture, cellular differentiation, stromal composition, and immune infiltration. Molecular profiling further identifies genomic alterations, transcriptomic signatures, proteomic pathways, and epigenetic modifications associated with therapeutic response and prognosis. Clinical information—including laboratory investigations, medication history, comorbidities, treatment records, and longitudinal follow-up—adds essential context to support personalized prediction models.[24]

Artificial intelligence enables harmonization of these heterogeneous datasets through multimodal representation learning. Advanced computational models align imaging biomarkers with molecular signatures and clinical variables, identifying biological relationships that are difficult to recognize using conventional statistical approaches. Such comprehensive integration enables digital twins to generate individualized predictions while adapting continuously as new patient information becomes available.[25]

6. Digital Twins in Diagnostic Radiology

Medical imaging forms one of the principal pillars of oncology digital twins because radiological examinations provide non-invasive assessment of tumor characteristics throughout the disease course. Computed tomography, magnetic resonance imaging, positron emission tomography, mammography, ultrasound, and hybrid imaging techniques collectively generate vast quantities of diagnostic information that can be incorporated into virtual patient models.[26]

Deep learning algorithms automatically identify tumors, segment anatomical structures, quantify lesion volume, and characterize imaging phenotypes associated with disease aggressiveness. Digital twins continuously update these imaging-derived features following chemotherapy, immunotherapy, surgery, or radiation therapy, allowing clinicians to visualize changes in tumor biology over time.

Radiomics has significantly expanded the clinical value of medical imaging by extracting hundreds of quantitative imaging biomarkers that describe tumor heterogeneity, texture, vascularity, and spatial organization. Rather than relying solely on visual interpretation, digital twins integrate these quantitative imaging features with molecular and clinical information to generate more accurate predictions regarding disease progression and therapeutic response.[27]

Longitudinal imaging analysis further enables continuous monitoring of treatment effectiveness. Changes in tumor volume, metabolic activity, vascular characteristics, and tissue composition are incorporated into the digital twin, allowing early identification of treatment resistance and facilitating timely modification of therapeutic strategies.[28]

7. Computational Digital Pathology

Digital pathology has become another essential component of oncology digital twins. Whole-slide imaging technologies generate extremely high-resolution digital representations of tissue specimens, allowing artificial intelligence systems to analyze millions of microscopic image regions simultaneously.

Transformer-based computational pathology models identify subtle histomorphological patterns associated with tumor subtype, cellular differentiation, stromal remodeling, angiogenesis, necrosis, immune infiltration, and metastatic potential. These microscopic features are subsequently integrated into the patient's digital twin to improve diagnosis, prognostic prediction, and treatment planning.[29]

One of the most promising developments involves prediction of molecular alterations directly from histopathological images. Advanced deep learning models have demonstrated the ability to infer clinically relevant biomarkers such as EGFR mutations, KRAS mutations, HER2 amplification, microsatellite instability, and PD-L1 expression directly from tissue morphology. This capability may reduce dependence on expensive molecular testing while accelerating precision oncology workflows.[30]

Digital pathology also enables quantitative evaluation of the tumor microenvironment. Artificial intelligence can estimate immune cell density, stromal architecture, vascular remodeling, fibrosis, and spatial organization of malignant cells. These measurements provide valuable biological information that substantially enhances the predictive capabilities of oncology digital twins.[31]

8. Radiogenomics and Integrated Molecular Imaging

Radiogenomics represents one of the most important translational applications of digital twins by linking radiological imaging with genomic and molecular information. This interdisciplinary approach seeks to identify imaging phenotypes that reflect underlying molecular characteristics of tumors, enabling non-invasive prediction of clinically significant genetic alterations.[32]

Artificial intelligence models analyze imaging biomarkers together with genomic sequencing data to identify associations between tumor morphology and molecular pathways. Such integration enables prediction of driver mutations, molecular subtypes, gene-expression profiles, and treatment sensitivity using routine clinical imaging.

Within digital twin ecosystems, radiogenomics supports repeated molecular assessment throughout disease progression without requiring multiple invasive tissue biopsies. This dynamic capability is particularly valuable for metastatic disease, where repeated sampling may be clinically difficult or impossible.[33]

By continuously incorporating radiogenomic information, digital twins provide adaptive representations of tumor evolution, enabling clinicians to evaluate disease progression, therapeutic response, and emerging resistance mechanisms in real time.

9. Digital Twins in Immuno-Oncology

Immunotherapy has transformed modern cancer treatment; however, only a subset of patients experiences durable clinical benefit. Predicting immunotherapy response remains one of the most challenging problems in precision oncology.

Digital twins address this challenge by integrating genomic alterations, immune-cell composition, cytokine signaling pathways, spatial immunomics, digital pathology, radiological imaging, and clinical biomarkers into comprehensive computational models. These systems simulate interactions between tumor cells and the immune system, providing individualized estimates of treatment response.[34]

Artificial intelligence can quantify tumor-infiltrating lymphocytes, immune checkpoint expression, stromal barriers, inflammatory signaling pathways, and immune-cell spatial organization. Integration of these variables enables virtual simulation of immunotherapeutic interventions before treatment initiation.

Patient-specific digital twins may eventually support optimization of immune checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, bispecific antibodies, adoptive cellular therapies, and combination treatment strategies by predicting therapeutic efficacy while minimizing immune-related toxicities.[35]

10. Personalized Treatment Planning

Perhaps the greatest clinical advantage of oncology digital twins lies in individualized treatment optimization. Rather than applying standardized treatment protocols derived from population-level clinical trials, physicians can evaluate multiple therapeutic scenarios within the patient's virtual model before initiating therapy.

Simulation engines estimate expected tumor response, treatment toxicity, recurrence probability, progression-free survival, and overall survival under various treatment combinations. These computational experiments allow clinicians to compare chemotherapy regimens, targeted therapies, immunotherapy combinations, surgical approaches, and radiation treatment strategies while minimizing unnecessary patient risk.[36]

Because digital twins continuously incorporate updated clinical information, therapeutic recommendations evolve throughout the patient's disease course. This adaptive framework supports precision medicine by recognizing that cancer biology changes over time and requires dynamic rather than static treatment planning.

11. Adaptive Radiation Oncology

Radiation therapy remains a cornerstone of cancer management. However, tumor size, anatomical position, and surrounding normal tissues frequently change during treatment, limiting the effectiveness of conventional static radiation planning.

Digital twins overcome these limitations by continuously integrating sequential imaging acquired throughout radiation therapy. Artificial intelligence automatically updates tumor contours, predicts anatomical changes, estimates radiation sensitivity, and recommends individualized treatment modifications.

Such adaptive planning may improve tumor control while reducing unnecessary radiation exposure to surrounding healthy organs. By simulating multiple radiation strategies within the digital twin, clinicians can optimize dose distribution according to the patient's evolving anatomy and biological response.[37]

12. Surgical Planning and Intraoperative Decision Support

Digital twins are increasingly being explored for surgical oncology applications. Three-dimensional patient-specific models generated from radiological imaging provide detailed visualization of tumor location, vascular anatomy, adjacent organs, and critical neurovascular structures before surgery.

Artificial intelligence further enhances surgical planning by predicting resection margins, estimating operative complexity, assessing postoperative complications, and modeling functional outcomes. Virtual simulation enables surgeons to evaluate multiple operative approaches before entering the operating room.[38]

Integration of intraoperative imaging, robotic navigation systems, and real-time physiological monitoring may eventually allow digital twins to update continuously during surgery, providing dynamic guidance that improves surgical precision while minimizing complications.

13. Digital Twins in Drug Discovery and Clinical Trials

Development of new anticancer therapies is an expensive and time-consuming process associated with high failure rates. Digital twins offer new opportunities for accelerating drug discovery through computational simulation of therapeutic responses before laboratory or clinical testing.

Artificial intelligence integrates molecular biology, systems pharmacology, genomic information, and patient-specific disease models to predict drug efficacy, toxicity, resistance mechanisms, and optimal dosing strategies. These virtual experiments may substantially reduce development costs while improving clinical success rates.[39]

Digital twins also have important implications for clinical trial design. Instead of relying exclusively on traditional eligibility criteria, computational patient models may identify individuals most likely to benefit from experimental therapies, improving patient selection and reducing trial variability.

Virtual control groups generated through validated digital twins may further decrease recruitment requirements while preserving scientific rigor, potentially accelerating regulatory approval of innovative cancer therapies.[40]

14. Real-Time Clinical Decision Support

Modern oncology requires interpretation of enormous quantities of clinical information generated throughout diagnosis and treatment. Digital twins function as intelligent clinical decision-support systems by continuously integrating new laboratory results, imaging studies, pathology findings, genomic reports, and treatment outcomes.

Rather than replacing physician expertise, these systems provide evidence-based recommendations supported by predictive simulations and individualized risk estimates. Interactive dashboards enable multidisciplinary teams to visualize disease evolution, compare treatment options, estimate toxicity risks, and evaluate long-term outcomes in a patient-specific manner.[41]

As healthcare increasingly adopts electronic health records, wearable biosensors, remote monitoring technologies, and cloud-based clinical infrastructure, digital twins are expected to become central components of future precision oncology ecosystems, enabling continuous learning and adaptive patient care.[42]

15. Explainable Artificial Intelligence and Trustworthy Digital Twins

For oncology digital twins to become widely accepted in clinical practice, clinicians must understand how artificial intelligence reaches its predictions. Black-box algorithms that provide accurate results without explaining their reasoning may reduce physician confidence and limit adoption in high-stakes medical decision-making. Explainable artificial intelligence (XAI) addresses this challenge by making model predictions transparent, interpretable, and clinically meaningful.[43]

Several explainability techniques have been integrated into oncology digital twins. Saliency maps and attention heatmaps highlight image regions that contribute most strongly to diagnostic predictions, allowing radiologists and pathologists to verify whether the AI system is focusing on biologically relevant structures. SHAP (Shapley Additive Explanations) values estimate the contribution of individual clinical variables, genomic alterations, or laboratory biomarkers to a model's prediction, while counterfactual explanations demonstrate how changes in specific patient characteristics may influence treatment outcomes.[44]

Explainability also facilitates multidisciplinary communication. Physicians, surgeons, radiation oncologists, pathologists, and molecular biologists can interpret AI-generated evidence collectively, ensuring that computational predictions complement rather than replace clinical expertise. Transparent decision-support systems are likely to improve clinician confidence, increase patient acceptance, and support regulatory approval of digital twin technologies.[45]

16. Federated Learning, Cybersecurity, and Privacy Protection

Large-scale digital twins require access to diverse clinical datasets generated across multiple healthcare institutions. However, direct sharing of patient information raises important concerns regarding privacy, confidentiality, and regulatory compliance. Federated learning provides an effective solution by allowing institutions to collaboratively train artificial intelligence models without transferring sensitive patient data.[46]

In a federated learning framework, each participating institution trains the model locally using its own patient records. Instead of exchanging raw data, only encrypted model parameters are transmitted to a central server where they are securely aggregated into an improved global model. This approach preserves patient privacy while enabling continuous learning from geographically diverse populations.[47]

Additional privacy-preserving techniques, including differential privacy, secure multi-party computation, homomorphic encryption, and blockchain-based audit systems, further strengthen cybersecurity within digital twin ecosystems. These technologies reduce the risk of unauthorized data access while maintaining transparency and accountability throughout the data lifecycle.[48]

Cybersecurity remains equally important because digital twins continuously exchange information among imaging systems, pathology laboratories, genomic sequencing platforms, wearable devices, cloud computing infrastructure, and hospital information systems. Robust authentication protocols, encrypted communication channels, intrusion detection systems, and real-time threat monitoring are therefore essential components of future clinical implementations.[49]

17. Digital Biomarkers and Continuous Patient Monitoring

The expansion of wearable medical technologies has created new opportunities for continuously updating oncology digital twins throughout the patient's treatment journey. Modern wearable sensors can monitor heart rate, respiratory function, physical activity, sleep quality, temperature, oxygen saturation, and other physiological parameters outside traditional healthcare settings.[50]

These continuously generated data streams provide valuable digital biomarkers reflecting patient health status, treatment tolerance, and recovery. When integrated into digital twins, wearable-derived information enables real-time assessment of functional decline, adverse treatment effects, and disease progression.

Remote monitoring may also improve survivorship care by identifying early warning signs of recurrence, treatment-related complications, or declining quality of life. Instead of relying solely on scheduled hospital visits, clinicians could receive continuous updates from patient-specific digital twins, enabling earlier interventions and more personalized follow-up strategies.[51]

The integration of mobile health applications, home-based monitoring devices, laboratory biomarkers, and patient-reported outcomes further expands the scope of digital twins beyond hospital-based oncology into comprehensive longitudinal care.

18. Digital Twins in Cancer Survivorship and Long-Term Care

Advances in cancer treatment have substantially increased the number of long-term cancer survivors worldwide. Consequently, survivorship care has become an increasingly important component of oncology practice. Many survivors experience chronic complications including cardiovascular disease, endocrine disorders, cognitive impairment, fatigue, secondary malignancies, and psychosocial challenges.

Digital twins provide a framework for personalized survivorship management by continuously evaluating individual risk factors, treatment history, genetic susceptibility, lifestyle characteristics, and longitudinal clinical data. Artificial intelligence can estimate the probability of late toxicities while recommending individualized surveillance strategies and preventive interventions.[52]

For example, survivors treated with anthracycline chemotherapy may require long-term cardiovascular monitoring, whereas individuals exposed to thoracic radiation may benefit from personalized screening protocols for secondary malignancies. Digital twins enable simulation of these long-term health trajectories, supporting evidence-based survivorship planning that extends well beyond active cancer treatment.

Such individualized follow-up strategies have the potential to improve quality of life while reducing unnecessary investigations and healthcare costs.

19. Emerging Innovations and Autonomous Oncology Ecosystems

Rapid advances in artificial intelligence continue to expand the capabilities of oncology digital twins. Foundation models trained on multimodal biomedical data are expected to improve prediction accuracy across diverse cancer types while requiring less task-specific retraining.

Generative artificial intelligence is likely to accelerate drug discovery by designing novel molecular structures, identifying therapeutic targets, simulating protein interactions, and generating synthetic biomedical datasets for research. Reinforcement learning algorithms may optimize adaptive treatment strategies by continuously learning from patient outcomes and modifying recommendations over time.[53]

Digital twins may eventually operate within fully integrated intelligent oncology ecosystems that combine radiology, pathology, genomics, immunology, wearable technologies, robotic surgery, adaptive radiation therapy, pharmacy systems, and electronic health records into unified clinical platforms. Such ecosystems could support continuous disease monitoring, automated risk assessment, personalized therapeutic optimization, and real-time multidisciplinary collaboration.

Although physician oversight will remain indispensable, these technologies may substantially improve efficiency, precision, and consistency across the entire continuum of cancer care.

20. Future Perspectives

The future of precision oncology is increasingly centered on comprehensive computational models capable of representing each patient as a continuously evolving biological system rather than a static clinical diagnosis. Digital twins embody this paradigm shift by integrating multimodal biomedical information into adaptive virtual representations that evolve alongside the patient's disease.

Future research should prioritize large prospective clinical studies evaluating real-world performance across diverse healthcare systems and patient populations. Standardization of imaging protocols, genomic sequencing methods, pathology workflows, data interoperability, and regulatory frameworks will be essential for widespread clinical implementation.[54]

International collaboration among clinicians, computer scientists, biomedical engineers, molecular biologists, regulatory agencies, and industry partners will accelerate the development of validated digital twin platforms capable of supporting routine oncology practice.

Advances in explainable AI, efficient foundation models, federated learning, quantum computing, and cloud-based healthcare infrastructure are expected to further enhance scalability, computational efficiency, and accessibility in both academic and community healthcare settings.[55]

21. Discussion

Digital twins represent one of the most significant advances in artificial intelligence–driven precision oncology by enabling dynamic, patient-specific computational modeling throughout the cancer care continuum. Unlike conventional predictive algorithms that analyze isolated datasets, digital twins continuously integrate radiological imaging, digital pathology, genomic sequencing, laboratory biomarkers, clinical documentation, and longitudinal patient information into unified computational ecosystems.

Their ability to simulate disease progression, estimate therapeutic response, optimize treatment selection, predict toxicity, and support survivorship planning highlights their potential to transform personalized cancer medicine. Applications across diagnostic imaging, computational pathology, radiogenomics, immunotherapy, adaptive radiation therapy, surgical planning, and drug development demonstrate the broad translational value of this technology.[56]

Nevertheless, successful implementation depends upon overcoming several important challenges. Data heterogeneity, limited interoperability, computational resource requirements, algorithmic bias, cybersecurity concerns, privacy protection, regulatory approval, and clinician acceptance remain significant barriers to widespread adoption. Addressing these issues will require multidisciplinary collaboration together with rigorous prospective validation and transparent governance frameworks.[57]

22. Conclusion

Artificial intelligence–driven digital twins are redefining the future of precision oncology by creating continuously evolving virtual representations of individual patients capable of integrating multimodal biomedical information into clinically actionable insights. Their ability to combine radiology, pathology, genomics, molecular biology, clinical records, wearable technologies, and real-time monitoring enables personalized prediction, adaptive treatment planning, and long-term survivorship management.[58]

As artificial intelligence technologies continue to mature, digital twins are expected to become increasingly accurate, scalable, interpretable, and clinically applicable. Integration with foundation models, federated learning, explainable AI, generative artificial intelligence, and advanced computational infrastructure will further enhance their role in personalized cancer care.[59]

Although important scientific, technical, ethical, and regulatory challenges remain, ongoing interdisciplinary research is steadily advancing digital twins toward routine clinical implementation. By enabling individualized simulation of disease evolution and therapeutic response, these systems have the potential to transform oncology from a predominantly reactive discipline into a predictive, preventive, adaptive, and highly personalized model of cancer care, ultimately improving patient outcomes and supporting the next generation of precision medicine.[60]

References

1. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.
2. Kumar RMH. Childhood-Oncology Intelligence for Predicting Cancer Emergence, Optimizing Precision Therapies, and Simulating Lifelong Outcomes in Pediatric Malignancies Using Autonomous Foundation Models. Int J Drug Deliv Technol.2026;16(65s):162-173.DOI:10.25258/ijddt.16.65s.19
3. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881-4.
4. Rajendran LKK. Hematological Malignancy Identification via K-means based ROI Extraction. International Journal of Clinical Research in Medical Sciences. 2026;1(2):1-10. Doi:10.67231/kt1w3e73.
5. Maradi Hemanth Kumar R. Dynamic Digital Twins in Oncology: Foundation AI Models for Real-Time Predictive and Personalized Cancer Care. Power System Protection and Control. 2025;53(4):549-563. Doi:10.46121/pspc.53.4.38.
6. Kumar RMH. Pan-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models. Power System Protection and Control. 2023;51(4):92-100. Doi:10.46121/pspc.51.4.8.
7. Rajendran LKK. Identifying Determinants of Outcome in Post-Radiotherapy Cervical Carcinoma Requiring Adjuvant Surgery. International Journal of Clinical Research in Medical Sciences. 2026;1(2):1-10. Doi:10.67231/3acej759.
8. Maradi Hemanth Kumar R. AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology. Power System Protection and Control. 2023;51(4):66-83. Doi:10.46121/pspc.51.4.7.
9. Rajendran LKK. Machine Learning–Driven Symptom-Based Cancer Risk Stratification:A Systematic Review of Clinical Prediction Models and Methodological Rigor. Int J Drug Deliv Technol. 2026;16(40s):242-253.Doi:10.25258/ijddt.16.40s.26.
10. Kumar RMH. Maternal–Fetal Oncology Intelligence: Self-Evolving Foundation Models and Digital Twin Ecosystems for Precision Cancer Prediction, Treatment Optimization, and Maternal–

Fetal Outcome Forecasting. Int J Drug Deliv Technol. 2026;16(65s):174-185. DOI: 10.25258/ijddt.16.65s.20
11. Rajendran OK. Bias, Fairness, and Ethical Challenges in Artificial Intelligence: A Comprehensive Review of Causes, Impacts, and Mitigation Strategies. Scientific Culture. 2026;12(2.1):13001-13010. Doi:10.5281/zenodo.20374091.
12. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56. Doi:10.1038/s41591-018-0300-7.
13. Kumar RMH. Precision Oncofertility: Integrating Genomics, Reproductive Biomarkers, Treatment Toxicity Profiles, and Foundation Models for Fertility Preservation in Men and Women with Cancer. Int J Drug Deliv Technol. 2026;16(65s):186-200. DOI: 10.25258/ijddt.16.65s.21
14. Rajendran OK. Clinical Translation of Artificial Intelligence in Oncology: Real-World Validation, Workflow Integration, and Precision Medicine Applications. Int J Drug Deliv Technol. 2026;16(49s):956-964. Doi:10.25258/ijddt.16.49s.110.
15. Rajendran LKK. Interpretable Machine Learning for Early Mortality Prediction in Acute Myeloid Leukemia: A Decision Tree–Based Retrospective Cohort Study. Int J Drug Deliv Technol. 2026;16(40s):231-241.Doi:10.25258/ijddt.16.40s.25.
16. Kumar RMH. Self-Evolving Digital Twin Ecosystems for Early Detection and Precision Management of Breast, Lung, Colorectal, and Ovarian Cancers. Int J Drug Deliv Technol. 2026;16(65s):201-212. DOI: 10.25258/ijddt.16.65s.22
17. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24–29. Doi:10.1038/s41591-018-0316-z.
18. Rajendran OK. Generative AI for Synthetic Medical Image Generation in Oncology: Addressing Data Scarcity in AI-Driven Cancer Diagnosis. Int J Drug Deliv Technol. 2026;16(49s):1010-1016. Doi:10.25258/ijddt.16.49s.117.
19. Rajendran LKK. Integrated Prognostic Modeling of Tumor Stage, Multimodal Therapy, and Functional Status in Lung Cancer Survival: A Real-World Cohort Study. Scientific Culture. 2026;12(5):567-576. Doi: 10.5281/zenodo.20738481.
20. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. arXiv. 2021. Doi:10.48550/arXiv.2108.07258.
21. Rajendran LKK. Integrative Pharmacogenomic Analysis of Drug Response Heterogeneity Across Cancer Cell Lines: Insights From Large-Scale GDSC Data. Scientific Culture. 2026;12(4):7537-7546. Doi:10.5281/zenodo.20767386.
22. Acs B, Rantalainen M, Hartman J. Artificial intelligence as the next step towards precision pathology. J Intern Med. 2020;288(1):62–81. Doi:10.1111/joim.13030.
23. Rajendran OK. Tumor Microenvironment Interaction-Guided Graph Neural Networks for Survival Prediction from Whole-Slide Pathology Images. Int J Drug Deliv Technol. 2026;16(49s):481-488. Doi:10.25258/ijddt.16.49s.50.
24. Rajendran LKK. Evaluating the Association of Cancer-Related Risk Factors With Multisystem Health: Insights Into Fertility, Cardiovascular, and Renal Indicators. Scientific Culture. 2026;12(4):7520-7527.Doi:10.5281/zenodo.20767374.
25. Rajendran LKK. From Prediction to Precision: An Externally Validated Deep Learning–Based Survival and Adjuvant Therapy Recommendation System for Resected Stage III Non–Small Cell Lung Cancer. Int J Drug Deliv Technol. 2026;16(30s):430-438.doi:10.25258/ijddt.16.30s.41.
26. Kumar RMH. Multimodal foundation AI models in precision oncology: Integrating radiomics, pathomics, multi-omics, and clinical intelligence systems. Power System Protection and Control. 2024;52(4):189-204. Doi:10.46121/pspc.52.4.16.
27. Rajendran LKK. From Prediction to Practice: A Machine Learning–Based Clinical Decision Support Tool for Bevacizumab Risk Stratification in Oncology. Int J Drug Deliv Technol. 2026;16(30s):414-429. Doi:10.25258/ijddt.16.30s.40.
28. Rajendran OK. Self-supervised multimodal Learning for early cancer detection across Imaging and genomics. Power System Protection and Control. 2024;52(4):167-178. Doi:10.46121/pspc.52.4.14.
29. Rajendran OK. Explainable AI-Driven Clinical. Decision Support Systems in Precision Oncology:Interpretable Models for Multimodal Cancer Care. Scientific Culture. 2026;12(2.1):12359-12369. Doi:10.5281/zenodo.20328194.
30. Rajendran LKK. Impact of Treatment Modalities on Fertility, Sexual Function, and Psychological Outcomes in Testicular Cancer Survivors: A Comprehensive Review. Int J Drug Deliv Technol. 2026;16(30s):447-453. Doi:10.25258/ijddt.16.30s.43.
31. Rajendran LKK. Intelligent Omics-Driven Patient Stratification for Cancer Therapeutic Re-profiling. International Journal of Clinical Research in Medical Sciences. 2026;1(1):1-11. Doi:10.67231/gv5hck05.
32. Rajendran LKK. Cancer nanomedicine: utilizing the enhanced permeability and retention (EPR) effect to deliver high payloads of chemotherapeutic agents directly to tumor sites. Power System Protection and Control. 2024;52(2):123-129. Doi:10.46121/pspc.52.2.12.
33. Kather JN, Calderaro J. Development of AI in digital pathology. Nat Rev Clin Oncol. 2020;17(10):591–595. Doi:10.1038/s41571-020-00431-0.
34. Rajendran OK. AI-based radiogenomic Models for predicting immunotherapy response In solid tumors. Power System Protection and Control. 2023;51(4):24-37. Doi:10.46121/pspc.51.4.4.
35. Rajendran LKK. Enhanced Predictive Analytics for Early Malignancy Discovery in Routine Screening.

International Journal of Clinical Research in Medical Sciences. 2026;1(1):1-10. Doi:10.67231/grams870.
36. Rajendran OK. Machine Learning-Based Prediction of Chemotherapy Toxicity in Colorectal Cancer: A Personalized Risk Stratification Approach. Scientific Culture. 2026;12(5.1):942-952. Doi:10.5281/zenodo.20767359.
37. Rajendran OK. Federated radiology AI Models for multi-institutional cancer diagnosis Without data sharing. Power System Protection And Control. 2023;51(4):38-54. Doi:10.46121/pspc.51.4.5.
38. Kumar RMH. AI-augmented immuno-oncology: Foundation models for predicting immune response, resistance, and precision immunotherapy. Power System Protection and Control. 2024;52(2):193-208. Doi:10.46121/pspc.52.2.18.
39. Rajendran OK. Deep Reinforcement Learning in Oncology: Advances in Cancer Imaging, Radiotherapy, and Personalized Treatment. Scientific Culture. 2026;12(5):597-606. Doi:10.5281/zenodo.20767337.
40. Rajendran OK. DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING. Power System Protection and Control. 2025;53(3):313-328. Doi:10.46121/pspc.53.3.21.
41. Lu MY, Chen TY, Williamson DFK, et al. AI-based pathology predicts origins for cancers of unknown primary. Nature. 2021;594(7861):106–110. Doi:10.1038/s41586-021-03512-4.
42. Rajendran OK. Artificial Intelligence in Oncologic Imaging: Deep Learning, Radiomics, and Clinical Integration for Precision Cancer Diagnosis. Int J Drug Deliv Technol. 2026;16(50s):871-880. Doi:10.25258/ijddt.16.50s.92.
43. Bilal M, Raza SEA, Azam A, et al. Development and validation of a weakly supervised deep learning framework to predict the risk of colorectal cancer recurrence from histology images. Lancet Oncol. 2021;22(11):153–163. Doi:10.1016/S1470-2045(21)00430-5.
44. Rajendran OK. DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA. Power System Protection and Control. 2025;53(4):486-501. Doi:10.46121/pspc.53.4.33.
45. Rajendran LKK. Genomic profiling: utilizing Multi-omics data to identify potential Therapeutic targets and resistance markers. Power System Protection and Control. 2024;52(4):159-166. Doi:10.46121/pspc.52.4.13.
46. Rajendran OK. Artificial Intelligence–Driven Multimodal Imaging for Cancer During Pregnancy: Advances in Maternal–Fetal Diagnostics and Precision Oncology. Int J Drug Deliv Technol. 2026;16(50s):862-870. Doi:10.25258/ijddt.16.50s.91.
47. Rajendran LKK. Immunotherapy and cell Therapy: developing CAR-T cell therapies and Other immune-based treatments for cancer and Autoimmune diseases. Power System Protection and Control. 2023;51(2):64-77. Doi:10.46121/pspc.51.2.7.
48. Rajendran OK. FOUNDATION MODEL–DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE. Power System Protection and Control. 2024;52(2):154-163. Doi:10.46121/pspc.52.2.14.
49. Rajendran LKK. Theranostics: integrating Diagnostic imaging agents and therapeutic Drugs into a single multifunctional nano-Platform for real-time monitoring of treatment. Power System Protection and Control.2025;53(2):376-386. Doi:10.46121/pspc.53.2.31.
50. Rajendran LKK. Mechanisms driving Immunotherapy resistance in colorectal cancer Liver metastases. Power System Protection and Control. 2024;52(1):29-37. Doi:10.46121/pspc.52.1.5.
51. Ching T, Himmelstein DS, Beaulieu-Jones BK, et al. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface. 2018;15(141):20170387. Doi:10.1098/rsif.2017.0387.
52. Litjens G, Kooi T, Bejnordi BE, et al. A survey on deep learning in medical image analysis. Med Image Anal. 2017;42:60–88. Doi:10.1016/j.media.2017.07.005.
53. Hemanth Kumar RM. Integrated Transcriptomic and 3 Learning Framework Identifies a Blood-Based Biomarker Signature for Anthracycline-Induced Cardiotoxicity in Juvenile Cancer Survivors. Int J Drug Deliv Technol. 2026;16(40s):219-230. Doi:10.25258/ijddt.16.40s.24.
54. Mobadersany P, Yousefi S, Amgad M, et al. Predicting cancer outcomes from histology and genomics using convolutional networks. Proc Natl Acad Sci USA. 2018;115(13):E2970–E2979. Doi:10.1073/pnas.1717139115.
55. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749–762. Doi:10.1038/nrclinonc.2017.141.
56. Azizi S, Mustafa B, Ryan F, et al. Big self-supervised models advance medical image classification. Nature. 2021;594(7864):104–110. Doi:10.1038/s41586-021-03476-6.
57. Dosovitskiy A, Beyer L, Kolesnikov A, et al. An image is worth 16×16 words: transformers for image recognition at scale. arXiv. 2020. Doi:10.48550/arXiv.2010.11929.
58. Rajendran OK. DeepDRA: A Deep Learning Framework for Drug Repurposing and Cancer Drug Response Prediction Using Multi-Omics Data. Scientific Culture. 2026;12(3):68-77. Doi:10.5281/zenodo.12326001.
59. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.
60. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. Nature. 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.